Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.47 |
| ▸ | FAP | Q12884 | 6/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30574559 | 0.94 | DPP4 (0.48) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL26210828 | 0.88 | DPP4 (0.53) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL26210873 | 0.88 | ATM (0.44) | DPP4MMP2ATMCYP3A4PEPD | |
| SCHEMBL25383852 | 0.87 | DPP4 (0.47) | DPP4DPP7FAPDPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL25383874 | 0.85 | DPP4 (0.49) | DPP4DPP7FAPDPP8DPP9 | |
| Trifluoroacetic Acid SCHEMBL30574543 | 0.83 | DPP4 (0.48) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL30574558 | 0.80 | CACNA1B (0.44) | MMP2 | |
| SCHEMBL26210945 | 0.79 | DPP4 (0.58) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL26439626 | 0.78 | DPP4 (0.52) | DPP4DPP7FAPDPP8DPP9 | |
| SCHEMBL22901867 | 0.77 | DPP4 (0.51) | DPP4DPP7FAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | DPP4 570/4885DPP7 369/4885FAP 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.